Skip to main content
. 2015 Oct 12;6(33):34953–34967. doi: 10.18632/oncotarget.5547

Figure 1. Skp1 in lung cancer.

Figure 1

A. Representative Western blot analyses of lysates of tumor and adjacent normal lung tissues harvested from NSCLCs (n = 64). B. The densitometry analysis of the Western blot results. C. Immunohistochemistry of Skp1 in NSCLCs using an anti-Skp1 antibody. Size bar, 50 μm. D. The immunoreactivity score was calculated. E. Overall survival of the 64 patients. F–J. A549 and H1975 cells were transfected with Skp1 specific siRNAs (F), the cell proliferation were analyzed by trypan blue exclusion analyses (G), and the clonogenic activity of cells was tested by the Flat plate clone formation assay (H, I). The cell cycle distribution of H1975 cells were analyzed (J). K, L. Effects of three Skp1-targeting compounds on lung cancer cells. The compounds were identified by structure-based high-throughput virtual screening for Skp1 inhibitors (See also Figure S1). Synchronous or asynchronous H1975 cells were treated with or without the compounds, and cell cycle distribution was determined (K). Western blot analysis of lysates of the cells treated with indicated compounds (L). Evo, Evodiamine; Lir, Liriodenine; 6-OAP, 6-O-angeloylplenolin.